Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Collegium Pharmaceutical (COLL) Change in Intangibles (2018 - 2020)

Collegium Pharmaceutical has reported Change in Intangibles over the past 2 years, most recently at $1.4 million for Q2 2020.

For Q2 2020, Change in Intangibles changed N/A year-over-year to $1.4 million; the TTM value through Dec 2020 reached $368.2 million, changed N/A, while the annual FY2020 figure was $368.2 million, N/A changed from the prior year.
Change in Intangibles for Q2 2020 was $1.4 million at Collegium Pharmaceutical, down from $366.8 million in the prior quarter.
Over five years, Change in Intangibles peaked at $366.8 million in Q1 2020 and troughed at $116000.0 in Q2 2018.